Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
AVITA Medical
RCEL
AVITA Medical
High Valuation Will Constrain Recovery Amid Regulatory And Cost Pressures
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
23 Aug 25
Updated
23 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
62.6% overvalued
intrinsic discount
23 Aug
US$4.88
Loading
1Y
-48.0%
7D
-12.1%
Author's Valuation
US$3.0
62.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
62.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-57m
119m
2014
2017
2020
2023
2025
2026
2028
Revenue US$119.0m
Earnings US$19.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
29.72%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.13%
Calculation
US$19.34m
Earnings '28
x
5.31x
PE Ratio '28
=
US$102.76m
Market Cap '28
US$102.76m
Market Cap '28
/
27.86m
No. shares '28
=
US$3.69
Share Price '28
US$3.69
Share Price '28
Discounted to 2025 @ 7.12% p.a.
=
US$3.00
Fair Value '25
